Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences
October 31, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to present at upcoming investor conferences
Atyr_Logo.png
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 08, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Atyr_Logo.png
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 02, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Atyr_Logo.png
aTyr Pharma to Participate in September Investor Conferences
August 21, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Participate in September Investor Conferences
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 
August 13, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
August 06, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
Atyr_Logo.png
aTyr Pharma Announces Research Study with Stanford Medicine
July 30, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces research study with Stanford Medicine to explore role of anti-NRP2 antibodies in glioblastoma multiforme (GBM), form of brain cancer.
Atyr_Logo.png
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 22, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 03, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Atyr_Logo.png
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)